Activating HER2 mutations are very rare [11].
However, several single-nucleotide polymorphisms
(SNPs) have been identified and two have been extensively
studied in relation to breast cancer. One SNP
corresponds to a residue in the transmembrane region at
codon 655 [12] and encodes either isoleucine (Ile; ATC)
or valine (Val; GTC).